LLY stock forecast, quote, news & analysis

Key Takeaways

• Eli Lilly shares are trading near $1,178 as of mid-July 2026, up approximately 7.3% over the trailing 30-day period and roughly 55% over the past year.
• The company's $2.8 billion acquisition of AtaiBeckley, announced in mid-July, marks a strategic entry into psychedelic-based neuroscience therapies for treatment-resistant depression.
• First-quarter 2026 results surpassed expectations, with revenue rising 56% year-over-year to $19.8 billion, driven by Mounjaro and Zepbound.
• Foundayo, Lilly's oral GLP-1 pill launched in April, faces scrutiny after IQVIA data showed flat weekly prescriptions, falling well below the launch trajectory of Novo Nordisk's oral Wegovy.
• Multiple Wall Street firms — including UBS, JPMorgan, Truist, and Bank of America — raised price targets in July, with consensus now near $1,284 and UBS targeting $1,425.
• Second-quarter earnings are scheduled for August 5, with Foundayo sales and Mounjaro international momentum serving as key investor focal points.

Current Market Snapshot

Eli Lilly and Company (LLY) shares have delivered a strong 2026 thus far, climbing roughly 11% year-to-date and recently touching an all-time high of $1,249.45 on July 7. The stock has since pulled back modestly, trading near $1,178 as of mid-July, as investors weigh robust underlying business momentum against emerging questions about the launch trajectory of Foundayo, the company's oral obesity therapy. With a market capitalization exceeding $1.1 trillion, Lilly remains the world's most valuable healthcare company. The broader pharmaceutical and biotech sector has benefited from a rotation into defensive equities amid technology-sector volatility, providing additional tailwinds for established drugmakers with strong earnings visibility.

Eli Lilly (LLY) Business Overview and Competitive Position

Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly is a global pharmaceutical company that researches, develops, manufactures, and commercializes medicines across multiple therapeutic areas. Its cardiometabolic franchise — headlined by the GLP-1 receptor agonists Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity — has become the company's dominant growth engine, accounting for roughly two-thirds of total revenue. Beyond diabetes and obesity, Lilly maintains a diversified portfolio spanning oncology, immunology, and neuroscience, with notable products including Verzenio, Taltz, Ebglyss, Omvoh, Jaypirca, and the Alzheimer's therapy Kisunla. The company holds a Composite Rating of 98 and the highest possible EPS Rating of 99 from IBD, reflecting broad institutional confidence in its growth trajectory. Institutional investors own approximately 82.5% of outstanding shares.

Recent Developments Driving LLY

The most significant recent catalyst is Lilly's July 16 announcement that it will acquire AtaiBeckley in an all-cash transaction valued at $2.8 billion upfront, with up to $1 billion in additional contingent value rights tied to clinical and regulatory milestones. The deal gives Lilly access to BPL-003, a Phase III-ready intranasal neuroplastogen for treatment-resistant depression. UBS reiterated its Buy rating following the announcement, citing alignment with CEO Dave Ricks's stated interest in neuropsychiatry as a large, underpenetrated market.

On the product front, the Medicare GLP-1 Bridge program launched on July 1, enabling eligible Part D beneficiaries to access Zepbound and Foundayo for $50 per month through December 2027. While the program also covers rival NVO therapies, it substantially broadens the addressable patient population.

However, Foundayo prescription data has introduced uncertainty. According to IQVIA data cited in a Jefferies note, weekly prescriptions have been flat for five consecutive weeks, reaching only 19,550 at week 13 versus more than 105,000 for Novo Nordisk's oral Wegovy at the same point post-launch. Jefferies projects approximately $71 million in debut-quarter Foundayo sales, well below the consensus estimate of roughly $130 million. Late PBM coverage by CVS and the newness of the orforglipron molecule are cited as mitigating factors.

On the regulatory front, an FDA advisory committee meeting scheduled for late July is set to debate domestic peptide manufacturing rules — a decision with direct implications for Lilly's injectable GLP-1 franchise and compounded drug competition. Separately, a federal appeals court revived a lawsuit by TEVA against Lilly related to the osteoporosis drug Forteo.

Analyst sentiment has remained broadly bullish throughout the month. UBS lifted its target to $1,425, RBC Capital raised its target to $1,500, JPMorgan moved to $1,400, and Bernstein raised to $1,385 — all citing GLP-1 momentum, international expansion, and pipeline diversification.

Trending AI Robots

For investors seeking data-driven trading strategies, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI-powered trading bots. Tickeron operates hundreds of AI-driven trading bots that collectively trade thousands of tickers across equities, ETFs, and forex markets, but only the most consistent and relevant performers are featured in this section. These bots employ a range of strategies — from short-term swing trades to longer-duration trend-following approaches — and are evaluated based on real-time performance metrics including win rates, drawdown profiles, and trade frequency. Traders and investors can browse the trending section to identify bots aligned with their own risk tolerance and market outlook.

2026 Outlook and What Investors Should Watch

The August 5 second-quarter earnings report represents the most immediate catalyst for LLY shareholders. Investors will scrutinize Foundayo's reported quarterly revenue against the wide gap between Jefferies' $71 million estimate and the $130 million consensus, as well as whether Mounjaro's international expansion — which grew 81% in Q1 — maintains its pace. Volume-versus-price dynamics remain critical: realized prices declined approximately 13% in Q1, and the investment thesis depends on demand growth continuing to outrun that compression.

Beyond earnings, the FDA peptide compounding meeting could reshape the competitive landscape for injectable GLP-1 therapies. The expected regulatory filing for retatrutide — Lilly's triple-agonist GLP-1/GIP/glucagon candidate that demonstrated approximately 28% weight loss in Phase 3 studies — could provide another major catalyst in the second half of 2026. Additionally, the AtaiBeckley transaction is expected to close in the third quarter, subject to shareholder and regulatory approvals. Competitive pressure continues to build from NVO, as well as emerging challengers including VKTX and GPCR, both advancing oral GLP-1 candidates toward late-stage trials. Lilly's premium valuation — trading at roughly 41 times earnings — leaves limited room for disappointment, making execution across both the GLP-1 franchise and newer pipeline assets essential through year-end.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations